← All trials
NCT05852431
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Sep 30, 2026
- First posted
- May 10, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 360
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 89bio Ltd.Lead sponsor
- 89bio Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.